Home » Stocks » GWPH

GW Pharmaceuticals PLC (GWPH)

Stock Price: $135.73 USD -2.10 (-1.52%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $134.80 -0.93 (-0.69%) Jan 15, 7:37 PM
Market Cap 4.23B
Revenue (ttm) 488.06M
Net Income (ttm) -53.93M
Shares Out 376.28M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE 243.90
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $135.73
Previous Close $137.83
Change ($) -2.10
Change (%) -1.52%
Day's Open 137.90
Day's Range 134.79 - 141.50
Day's Volume 379,971
52-Week Range 72.48 - 141.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Schaeffers Research - 1 day ago

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis...

Other stocks mentioned: ACB, APHA, ARNA, CGC, HEXO, OGI, SNDL, TAP
Seeking Alpha - 4 days ago

GW Pharmaceuticals plc. (GWPH) CEO Justin Gover on 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript)

InvestorPlace - 4 days ago

Many marijuana stocks show promise in 2021, but these specific stocks have the best shot to build upon their strong performances last year. The post The Top 7 Marijuana Stocks to Buy for Janua...

Other stocks mentioned: APHA, CRLBF, GTBIF, MO, TCNNF, CURLF
The Motley Fool - 5 days ago

These cannabis stocks currently have the most green.

Other stocks mentioned: APHA, CGC, CRON, TCNNF
Market Watch - 6 days ago

GW Pharmaceuticals PLC provided an upbeat outlook for fourth-quarter sales, amid strength in sales of Epidiolex, the first cannabis-based drug to be approved by the Food and Drug Administratio...

The Motley Fool - 6 days ago

Add these top growth stocks to your portfolio before it's too late.

Other stocks mentioned: BNTX, PFE, TSM
The Motley Fool - 1 week ago

The rapidly growing cannabis industry now has 10 companies at or above a $2 billion market cap.

Other stocks mentioned: CCHWF, CGC, CRLBF, CRON, CURLF, GRWG, GTBIF, IIPR, TCNNF
GlobeNewsWire - 1 week ago

LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group) under the same headline,...

Schaeffers Research - 3 weeks ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this past week and look ahead to how the cannabis indus...

Other stocks mentioned: CGC, HEXO, OGI, SNDL, YCBD
GlobeNewsWire - 3 weeks ago

EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized

The Motley Fool - 4 weeks ago

Analysts believe these pot stocks are budding with opportunity.

Other stocks mentioned: CCHWF, HRVSF, JUSHF, OGI
Seeking Alpha - 1 month ago

GW Pharmaceuticals Plc is a pharma company and a global leader in developing cannabinoid-based medicines. Its multiple sclerosis drug nabiximols (brand name Sativex) was the first natural cann...

InvestorPlace - 1 month ago

Medicinal cannabis is no longer speculative. There are truly impactful treatments out there, as well as investment-worthy marijuana stocks.

Other stocks mentioned: ABBV, ACB, ALEAF, CRON, CWBHF, HRVSF
GlobeNewsWire - 1 month ago

LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercializ...

Schaeffers Research - 1 month ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...

Other stocks mentioned: APHA, ARNA, OGI, SNDL, TLRY
Benzinga - 1 month ago

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts be...

GlobeNewsWire - 1 month ago

- Meeting Highlights Include New Long-Term D ata in Tuberous Sclerosis Comple x -

Market Watch - 1 month ago

Cannabis stocks continued their postelection rise from the ashes Monday, ahead of votes this week regarding decriminalization in the U.S. House of Representatives and the United Nations.

Other stocks mentioned: ACB, APHA, HMMJ, MJ, SNDL, TLRY
GlobeNewsWire - 1 month ago

LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercializ...

The Motley Fool - 1 month ago

Getting exposure to the cannabis industry's upside has never been safer or cheaper.

Other stocks mentioned: CGC, MO, TOKE
The Motley Fool - 1 month ago

Getting exposure to the marijuana industry has never been easier.

Other stocks mentioned: CGC, MO, TOKE
Schaeffers Research - 1 month ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...

Other stocks mentioned: ACB, APHA, ARNA, GNLN, IIPR, NBEV, OGI, TRPX
Seeking Alpha - 1 month ago

GW Pharmaceuticals plc (GWPH) CEO Justin Gover presents at Stifel Virtual Healthcare Conference (Transcript)

Seeking Alpha - 2 months ago

During a recessionary environment is historically when VCs make a ton of money.

Other stocks mentioned: CCHWF, CGC, CNBS, CNPOF, MJ, MSOS, POTX, TCNNF, THCX, TOKE, TRSSF, YOLO
Zacks Investment Research - 2 months ago

CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.

Other stocks mentioned: APHA, CGC, CNBS, CRON, GRWG, IIPR
GlobeNewsWire - 2 months ago

- Results from analysis of three P hase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis

Seeking Alpha - 2 months ago

Company saw a surprise upside in revenues and earnings for the latest quarter. Strong pipeline means a continued revenue stream into the future.

GlobeNewsWire - 2 months ago

LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercializ...

Schaeffers Research - 2 months ago

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to...

Other stocks mentioned: CGC, APHA, CRON, IIPR, NTEC, VFF, XXII, YCBD
24/7 Wall Street - 2 months ago

With the fourth quarter almost half over, and most of the third-quarter earnings reports long since posted, most on Wall Street are reasonably satisfied with the results.

Other stocks mentioned: TER, ARCB, GTES
Seeking Alpha - 2 months ago

GW Pharmaceuticals' latest earnings report reinforces the narrative that the company's future growth trajectory looks solid. Epidiolex still has a lot of growth potential in the short and long...

Yahoo Finance - 2 months ago

Election 2020: What cannabis legalization means for investors and the cannabis sector

Vivien Azer Cowen Managing Director and Senior Research Analyst discusses the election day and the impact of cannabis legalization on stocks. #cannabis #marijuana #cannabislegalization Subscri...

Other stocks mentioned: ACB, CGC, CRON, TLRY
Investors Business Daily - 2 months ago

GW Pharmaceuticals is an "underappreciated story," an analyst said as GWPH stock jumped higher on Wednesday for the second day running on better-than-expected third-quarter revenue. The post C...

InvestorPlace - 2 months ago

GW Pharmaceuticals (GWPH) news for Wednesday includes GWPH stock continuing to rise after the release of its Q3 earnings report yesterday. The post GW Pharmaceuticals News: Why GWPH Stock Is R...

Seeking Alpha - 2 months ago

GW Pharmaceuticals plc's (GWPH) CEO Justin Gover on Q3 2020 Results - Earnings Call Transcript

Market Watch - 2 months ago

Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabin...

The Motley Fool - 2 months ago

The cannabinoid prescription drug Sativex has already been approved in numerous countries for reducing spasticity caused by MS.

The Motley Fool - 2 months ago

Momentum for Epidiolex remains very strong.

Market Watch - 2 months ago

Shares of GW Pharmaceuticals PLC rallied 4.7% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform reported a narrowe...

Market Watch - 2 months ago

Shares of GW Pharmaceuticals PLC were indicated up more than 6% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform ...

GlobeNewsWire - 2 months ago

- Total revenue increased 51 percent to $ 137.1 million –  - Epidiolex for seizures associated with TSC launch ed in the U.S. - - Nabiximols Phase 3 program in MS spasticity now recruiting - -...

GlobeNewsWire - 2 months ago

CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of ca...

Kiplinger - 2 months ago

Investors keep waiting for marijuana stocks to come to life. In 2020, the Prime Alternative Harvest Index, which covers many of the major global cannabis companies, hasn't been good.

Other stocks mentioned: APHA, CURLF, IIPR, MJ, MO, MSOS, SMG, STZ, STZ.B
Zacks Investment Research - 2 months ago

GW Pharmaceuticals (GWPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Seeking Alpha - 2 months ago

Investors should study the various revenue streams for "epidiolex". Level of cash reserves important to judge likelihood of future share dilution.

GlobeNewsWire - 2 months ago

LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and ...

GlobeNewsWire - 2 months ago

-- Technology p rovide s a n ew w ay for the community to c ommunicate and c onnect -- -- Launching in collaboration with patient advocacy organizations, this web-based, i mage-recognition t e...

InvestorPlace - 3 months ago

Marijuana stocks typically have high levels of risk for investors, but these three stocks deserve to be on your radar. The post 3 Marijuana Stocks to Buy With Decriminalization on the Table ap...

Other stocks mentioned: MJ, STZ
CNBC Television - 3 months ago

Cannabis stocks surge on legalization hopes — Here's why

Vivien Azer, Cowen and Company, joins 'Power Lunch' to discuss the surge in cannabis stocks as investors anticipate legalization if there is a Biden presidency.

Other stocks mentioned: ACB, CGC, CRLBF, GTBIF, TLRY
InvestorPlace - 3 months ago

Investing in marijuana is speculative, but, with these marijuana ETFs you can get in on the cannabis investing game and reduce risk. The post The 5 Best Marijuana ETFs for Conservative Portfol...

Other stocks mentioned: MJ, THCX, TLRY, YOLO

About GWPH

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops vari... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
May 1, 2013
CEO
Justin Gover
Employees
901
Stock Exchange
NASDAQ
Ticker Symbol
GWPH
Full Company Profile

Financial Performance

In 2019, GWPH's revenue was $311.33 million, an increase of 2,344.31% compared to the previous year's $12.74 million. Losses were -$9.02 million, -96.94% less than in 2018.

Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for GWPH stock is "Buy." The 12-month stock price forecast is 182.50, which is an increase of 34.46% from the latest price.

Price Target
$182.50
(34.46% upside)
Analyst Consensus: Buy